Clinical Trials
139 trialsZAP-IT: ZN-c3 + Carboplatin + Pembrolizumab in mTNBC
Dana-Farber Cancer Institute
PAPAYA
Royal Marsden NHS Foundation Trust
Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies
M.D. Anderson Cancer Center
PERM
Royal Marsden NHS Foundation Trust
Stereotactic Radiosurgery and Immune Checkpoint Inhibitors With NovoTTF-200M for the Treatment of Melanoma Brain Metastases
Emory University
Pembrolizumab as Neoadjuvant Therapy for Resectable Stage IA3 to IIA Non-Small Cell Lung Cancer (NSCLC)
McGill University Health Centre/Research Institute of the McGill University Health Centre
PEACH
Royal Marsden NHS Foundation Trust
CMP-001 for Relapsed and Refractory Lymphoma
University of Iowa
Radiotherapy With Pembrolizumab in Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)
University of Erlangen-Nürnberg Medical School
A Phase II Study of Futibatinib and Pembrolizumab in Metastatic Microsatellite Stable Endometrial Carcinoma
M.D. Anderson Cancer Center
Study of Combined Decompressive Spine Radiosurgery and Pembrolizumab
Wake Forest University Health Sciences
IMRT Followed by Pembrolizumab in the Adjuvant Setting in Anaplastic Cancer of the Thyroid (IMPAACT): Phase II Trial Adjuvant Pembrolizumab After IMRT in ATC
M.D. Anderson Cancer Center
REPLACE
Translational Research in Oncology
Ibrutinib and PD-1 Blockade in High Risk Lymphocytic Leukemia
H. Lee Moffitt Cancer Center and Research Institute
Pembrolizumab in MarginalzoneLymphoma A MULTICENTER OPEN LABEL SINGLE-ARM PHASE II STUDY
University of Ulm
Pembrolizumab for Patients With PD-L1 Diffuse Large B Cell Lymphoma (DLBCL)
University of Chicago
Rucaparib and Pembrolizumab for Maintenance Therapy in Stage IV Non-Squamous Non-Small Cell Lung Cancer
University of Michigan Rogel Cancer Center
Breast-48
University of Virginia
MESO-PRIME
Royal Marsden NHS Foundation Trust
PRIMING
Royal Marsden NHS Foundation Trust
Oncomabs
Oslo University Hospital
Selinexor and Pembrolizumab for the Treatment of Cisplatin-Ineligible or Cisplatin-Refractory Locally Advanced or Metastatic Urothelial Carcinoma
University of California, Davis
INTEGRAL
The Methodist Hospital Research Institute
NBTXR3, Radiation Therapy, and Pembrolizumab for the Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Cancer
M.D. Anderson Cancer Center
Regorafenib in Combination With Pembrolizumab or Pembrolizumab for MSI-H Colorectal Cancer
University of Pittsburgh
Preoperative Immunotherapy (Pembrolizumab) for Patients With Colorectal Cancer and Resectable Hepatic Metastases
University of California, San Francisco
Study of Pembrolizumab and Mifepristone in Patients With Advanced HER2-negative Breast Cancer
University of Chicago
Aldesleukin and Pembrolizumab in Treating Patients With Advanced or Metastatic Kidney Cancer
University of Washington
Pembrolizumab and EDP1503 in Advanced Melanoma
University of Chicago
Pembrolizumab and Lenvatinib in Patients With Brain Metastases From Melanoma or Renal Cell Carcinoma
Yale University
APX005M in Combination With Systemic Pembrolizumab in Patients With Metastatic Melanoma
M.D. Anderson Cancer Center
Pembrolizumab With or Without Axitinib for Clear Cell Kidney Cancer in Patients Undergoing Surgery
University of California, San Francisco
Pembrolizumab in Untreated B-Cell Non-Hodgkin Lymphoproliferative Diseases
University of Washington
Pembro+Chemo in Brain Mets
University of Kentucky
Phase II Trial of Magrolimab and Cetuximab With Pembrolizumab or Docetaxel for Recurrent/Metastatic Head Neck Squamous Cell Carcinoma
M.D. Anderson Cancer Center
Study of Lenvatinib w/ Pembro in Black Participants w/Mismatch Repair-Prof Recurrent Endometrial Cancer
Virginia Commonwealth University
SABRseq
Peter MacCallum Cancer Centre, Australia
Ferumoxytol MRI in Assessing Response to Pembrolizumab in Patients With Glioblastoma
OHSU Knight Cancer Institute
PEMAZA
Technische Universität Dresden
Pembrolizumab in HNSCC With Residual Disease After Radiation
Yale University
IRRADIATE-Lung
NYU Langone Health
Study of Pembrolizumab and Radiotherapy in Liver Cancer
University Health Network, Toronto
Pembrolizumab And Lenvatinib In Leptomeningeal Metastases
Massachusetts General Hospital
ImmPACT Expanded Multiple Antigen Specific Endogenously Derived T Cells (MASE-T) to Patients With Metastatic Melanoma
Herlev Hospital
Pembrolizumab With Rituximab or Obinutuzumab in Treating Patients With Relapsed or Refractory Follicular Lymphoma or Diffuse Large B Cell Lymphoma
University of Washington
NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours
NuCana plc
Rintatolimod, Celecoxib and Interferon Alpha 2b With Pembrolizumab For the Treatment of Patients With Metastatic or Unresectable Triple Negative Breast Cancer
Roswell Park Cancer Institute
A Phase II Study to Evaluate the Efficacy and Safety of Pembrolizumab in Combination With Mitotane in Patients With Advanced Adrenocortical Carcinoma
M.D. Anderson Cancer Center
Dendritic Cell Therapy With Pembrolizumab for Metastatic or Unresectable Melanoma
Mayo Clinic
TUGETHER
Breast Cancer Trials, Australia and New Zealand